Non-selective beta-blockers in the prevention of first variceal bleeding. Is there any definite alternative?

Journal of Hepatology

Volumn 37, Issue 3, 2002, Pages 393-395

  Garcia Pagan, Juan Carlos ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ISOSORBIDE 5 NITRATE; PROPRANOLOL;

DRUG CONTRAINDICATION; DRUG EFFICACY; EDITORIAL; ESOPHAGUS VARICES BLEEDING; HUMAN; LIVER CIRRHOSIS; PORTAL HYPERTENSION; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; ESOPHAGUS VARICES; GASTROINTESTINAL HEMORRHAGE; NOTE;

ADRENERGIC BETA-ANTAGONISTS; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HUMAN; HUMANS;

EID: 0036708288     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00244-1     Document Type: Editorial

References (28)

1. The treatment of portal hypertension: A meta-analytic review
2. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multi-center study. The North Italian Endoscopic Club for the study and treatment of esophageal varices
3. Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: The TEST study
4. Updating consensus in portal hypertension: Report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension
5. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials
6. Pharmacological treatment of portal hypertension: An evidence-based approach
7. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study
8. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis
9. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding
10. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding
11. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding
12. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: A randomized controlled trial
13. Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis
14. Propranolol + placebo vs. propranolol + isosorbide-5-mononitrate in the prevention of the first variceal bleeding
15. Isosorbide mononitrate with nadolol compared to nadolol alone for prevention of first bleeding in cirrhosis. A double-blind, placebo-controlled randomized trial
16. Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers
17. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function
18. Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension
19. Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis
20. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis
21. A randomized controlled trial of endoscopic variceal band ligation for primary prophylaxis of variceal bleeding
22. Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites
23. Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis
24. Long-term administration of isosorbide-5-mononitrate does not impair renal function in cirrhotic patients
25. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: Long-term hemodynamic and renal effects
26. Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis
27. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding
28. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding